New Inhibitors for Xanthine Oxidase in Cancer Treatment
Author Information
Author(s): Kalra Sukirti, Jena Gopabandhu, Tikoo Kulbhushan, Mukhopadhyay Anup Kumar
Primary Institution: National Institute of Pharmaceutical Education and Research (NIPER)
Hypothesis
Can 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purinethiol selectively inhibit xanthine oxidase to improve the efficacy of 6-mercaptopurine in cancer therapy?
Conclusion
The study suggests that using APT or AHMP with 6MP could enhance cancer treatment by preventing the wasteful metabolism of 6MP.
Supporting Evidence
- The inhibitors APT and AHMP showed lower IC50 values for 6MP than for xanthine, indicating preferential inhibition.
- Both inhibitors were found to be non-toxic in acute toxicity studies in mice.
- The study suggests that APT and AHMP can effectively inhibit the conversion of 6MP to an inactive metabolite.
Takeaway
Researchers found two new drugs that can help a cancer medicine work better by stopping it from being broken down too quickly in the body.
Methodology
The study involved characterizing the inhibitors' effects on xanthine oxidase activity using IC50 values and kinetic parameters.
Limitations
The study primarily focused on in vitro experiments, and the effects in vivo may differ.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website